SCIENTIFIC PROGRAMME

Thursday, March 18, 2010

15:00 - 16:00 • Opening ceremony

Copper Hall

Opening Ceremony

Chair: V. Grégoire, Belgium
W. Knapp, Germany

1 **15:15**
HIGH-TECH MEDICINE IN THE FIGHT AGAINST CANCER - HOW MUCH MOLECULAR IMAGING DO WE NEED
M. Schwaiger (Germany)

Thursday, March 18, 2010

16:00 - 18:00 ● Symposium

Copper Hall

New perspectives and challenging issues in Molecular Imaging for Radiation Oncology

2 **16:00**
EUROPEAN REGULATIONS ON RADIOPHARMACEUTICALS - A PROFESSIONAL'S PERSPECTIVE
C. Decristoforo (Austria)

3 **16:30**
CLINICAL TRIAL PROSPECTIVE
S. Stroobants (Belgium)

Friday, March 19, 2010

08:45 - 10:30 • Symposium

Copper Hall

MULTI-TRACERS FOR MOLECULAR PROFILING

4 **08:45**
TUMOR MICROENVIROMENT AND CELLULAR ADAPTATION: OPPORTUNITIES FOR IMAGING
B. Wouters (Canada)

5 **09:15**
HOW TO IMAGE? (TRACERS) STATE OF THE ART AND FUTURE DEVELOPMENT
C. Halldin (Sweden)

6 **09:45**
HOW TO IMAGE QUANTITATIVELY? STATE OF THE ART AND FUTURE EQUIPMENT DEVELOPMENT
R. Boellaard (Netherlands)

10:15
DISCUSSION TIME

Friday, March 19, 2010

11:00 - 12:30 • Symposium

Copper Hall

TRANSLATING MOLECULAR IMAGING INTO CLINICAL PRACTICE

7 **11:00**
THE EGRF STORY FROM A MOLECULAR POINT OF VIEW
G. Van Dongen (Netherlands)

8 **11:25**
TUMOR MICROENVIRONMENT INLCUDING HYPOXIA
E. Aboagye (United Kingdom)

9 **11:50**
SIMULATION OF HYPOXIA PET TRACER DYNAMICS BASED ON TUMOUR TISSUE MICROSECTIONS
D. Mönnich (Germany), D. Thorwarth, E. Troost, J. Kaanders, W. Oyen, M. Alber

10 **12:00**
PET-IMAGING OF HYPOXIA USING 89ZR-LABELED CG250-F(AB')2
B. Hoeben (Netherlands), J. Kaanders, P. Laverman, E. Oosterwijk, W. Oyen, O. Boerman, J. Bussink

11 **12:10**
PRECLINICAL EVALUATION OF [18F]HX4, A NOVEL AND PROMISING HYPOXIA MARKER FOR PET IMAGING
L. Dubois (Netherlands), N. Lieuwes, M. Janssen, J. Secrest, A. Windhorst, G. van Dongen, H. Kolb, M. Öllers, J. Zhang, P. Lambin

12 **12:20**
TARGETING THE LACTATE TRANSPORTER MCT1 INDUCES A METABOLIC REARRANGEMENT THAT RADIOSENSITIZES TUMORS
P. Sonveaux (Belgium), F. Végran, M. Dewhirst, O. Feron

Friday, March 19, 2010
14:30 - 16:00 • Symposium

Copper Hall

Treatment Selection

13 **14:30**
IMPACT ON DISEASE STAGING BY NEW IMAGING MODALITIES
T. F. Hany (Switzerland)

14 **14:55**
TUMOUR BIOLOGY-GUIDED PROGNOSTICATION OF TREATMENT RESPONSE
H. Minn (Finland)

15 **15:20**
SCREENING FOR DISTANT METASTASES IN HEAD AND NECK CANCER PATIENTS BY FDG-PET(-CT) TO AVOID FUTILE TREATMENTS
R. de Bree (Netherlands), A. Senft, O. Hoekstra, D. J. Kuik, R. Golding, E. Comans, C. R. Leemans

16 **15:30**
PET TO AVOID FUTILE LARYNGOSCOPIES IN PATIENTS WITH SUSPICION OF RECURRENT LARYNGEAL CARCINOMA AFTER RADIOTHERAPY
R. de Bree, L. Van der Putten (Netherlands), O. Hoekstra, D. J. Kuik, E. Comans, C. R. Leemans

17 **15:40**
ROLE OF 18F-FDG PET/TC IN THE PREDICTION OF RESPONSE TO NEO-ADJUVANT CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: OUR EXPERIENCE
F. Matteucci (Italy), A. Marzullo, A. Moretti, R. Galassi, F. Lio, A. Moro, P. Morgagni, G. M. verdecchia

18 **15:50**
PRETREATMENT F-MISO HYPOXIC VOLUME IS PROGNOSTIC FOR LOCAL CONTROL AFTER SINGLE DOSE IRRADIATION IN FADU HSCC
B. Beuthien-Baumann (Germany), C. Schütze, R. Bergmann, B. Mosch, A. Yaromina, K. Brüchner, R. Greinke, F. Hessel, H. Thames, D. Zips, P. Mäding, M. Baumann

Friday, March 19, 2010

16:30 - 18:00 • Symposium

Copper Hall

TARGET SELECTION / DELINEATION

19 **16:30**
SEGMENTATION, (AUTO) DELINEATION, 4D PET/CT
J. Nuyts (Belgium)

20 **16:55**
CLINICAL REQUIREMENTS FOR TARGET VOLUME SELECTION/DELINEATION
U. Nestle (Germany)

21 **17:20**
USE OF GA-68-DOTATOC PET/CT FOR PLANNING THE STEREOTACTIC RT IN SCULL BASE MENINGIOMAS
F. Nyuyki (Germany), R. Graf, D. Fahdt, R. Michel, L. Geworski, W. Brenner, M. Plotkin

22 **17:30**
FDG-PET GUIDED IMRT FOR PATIENTS WITH CERVICAL CANCER
P. Grigsby (USA)

23 **17:40**
IMPACT OF 18-FDG PET STAGING ON TREATMENT PLANNING IN RADIOTHERAPY INCORPORATING ELECTIVE NODAL IRRADIATION FOR NON-SMALL CELL LUNG CANCER: PROSPECTIVE STUDY .
M. Kolodziejczyk (Poland), L. Kepka, M. Dziuk, A. Zawadzka, N. Szalus, A. Gizewska, K. Bujko

24 **17:50**
FIRST RESULTS FROM LIST MODE BASED TARGET DELINEATION IN HIGH PRECISION RADIOTHERAPY
I. Ernst (Germany), F. Buether, M. Dawood, P. Kraxner, C. Moustakis, M. Weckesser, O. Schober, K. Schäfers, N. Willich, T. Boelling

Saturday, March 20, 2010

08:30 - 10:00 • Symposium

Copper Hall

Dose Painting

25 **08:30**
DOSE-REDISTRIBUTION IN NON-SMALL CELL LUNG CANCER: IMAGING NEEDS AND FIRST CLINICAL EXPERIENCE
D. De Ruysscher (Netherlands)

26 **08:55**
PHYSICAL CONCEPTS/POTENTIAL LIMITATIONS/POTENTIAL ADVANTAGES
M. Alber (Germany)

27 **09:20**
INTENSITY-MODULATED RADIOTHERAPY FOR PROSTATE CANCER IMPLEMENTING MOLECULAR IMAGING WITH 18F-CHOLINE PET-CT TO DEFINE A SIMULTANEOUS INTEGRATED BOOST
M. Pinkawa (Germany), M. D. Piroth, R. Holy, J. Klotz, S. Nussen, T. Krohn, F. Mottaghy, M. J. Eble

28 **09:30**
BIOLOGICAL TARGET VOLUME (BTV) BOOST PHASE II STUDY ON DOSE-ESCALATION OF THE HIGH UPTAKE FDG-PET REGIONS INSIDE THE PRIMARY TUMOUR FOR NSCLC: THE TREATMENT PLANNING STRATEGY
W. van Elmpt (Netherlands), S. Petit, A. van der Salm, J. van der Stoep, A. Lakeman, J. J. Sonke, E. Damen, M. Öllers, J. Belderbos, D. De Ruysscher

29 **09:40**
PET-GUIDED DOSE PAINTING FOR MOVING TUMORS OF THE LUNG: A PRELIMINARY ANALYSIS CONTRASTING 3D AND 4D SCANS
M. Aristophanous (USA), A. Chen, J. Yap, J. Killoran, S. J. Park, R. Berbeco

30 **09:50**
OPTICAL IMAGING OF TUMOR RESPONSE TO RADIATION: PROBING VASCULAR, CELLULAR AND MOLECULAR CHANGES IN VIVO
R. DaCosta (Canada), M. Leung, E. Chen, P. Lindsay, D. Jaffray, A. Vitkin, R. Hill

Saturday, March 20, 2010

10:30 - 12:00 ● Symposium

Copper Hall

When, how and why molecular imaging for response evaluation and follow up

31 **10:30**
RADIATION ONCOLOGY PERSPECTIVE
K. Haustermans (Belgium)

32 **10:55**
NUCLEAR MEDICINE PERSPECTIVE
W. Weber (Germany)

33 **11:20**
ROLE OF 11C-CHOLINE PET/CT IN TOMOTHERAPY TREATMENT PLANNING OF LYMPH NODAL RELAPSE IN PROSTATE CANCER PATIENTS
M. Picchio (Italy), F. Alongi, E. Manca, C. Cozzarini, G. Berardi, C. Landoni, L. Gianolli, N. Di Muzio, C. Messa

34 **11:30**
THE ROLE OF 18FDG-PET -CT IN RESPONSE PREDICTION BEFORE, DURING AND AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR RECTAL CANCER.
M. Lambrecht (Belgium), C. Deroose, S. Roels, L. Mortelmans, F. Penninckx, E. Van Cutsem, K. Haustermans

35 **11:40**
FLT-PET-CT FOR EARLY TREATMENT RESPONSE MONITORING IN HEAD AND NECK TUMOURS
E. Troost (Netherlands), J. Bussink, A. Hoffmann, O. Boerman, W. Oyen, J. Kaanders

36 **11:50**
HYPOXIA IMAGING DURING RADIOCHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD-AND-NECK CANCER
D. Zips (Germany), N. Abolmaali, K. Zöphel, A. Abramyuk, C. Reiffenstuhl, S. Appold, J. Kotzerke, J. Steinbach, M. Baumann

Posters

BIOLOGICAL TREATMENT PLANNING

Abstract Nb.

37 PROMISING NEW ADVANCES TREATED AND DISCOVERY MOLECULAR BIOMARKER IN ADVANCED HEAD AND NECK CARCINOMA
A. E. Crisan (Romania), F. Badulescu, A. Badulescu

38 AN ASSESSMENT OF MOTION-BLURRING IN PET-GUIDED TREATMENT PLANNING USING A RADIOBIOLOGICAL ENDPOINT
R. Perrin (United Kingdom), S. Webb, M. Partridge

39 APOPTOSIS IMAGING BY PET 18F-ML-10: A POTENTIAL TOOL FOR RADIATION DOSE PAINTING
A. Shirvan (Israel), T. Davidson, A. Allen, A. Reshef, A. Steinmetz, I. Ziv

40 BIOLOGICAL IN-SITU DOSE PAINTING FOR IGRT (BIS-IGRT) BY USE OF DRUG-LOADED IMPLANTABLE FIDUCIALS AND SPACERS
M. Makrigiorgos (USA), S. Sridhar, A. D'Amico, P. Nguyen, R. Cormack

41 BIOLOGICALLY GUIDED RADIATION THERAPY: QUALITY ASSURANCE AND RESOURCE IMPLICATIONS IN LONGITUDINAL PET/CT STUDIES
S. Everitt (Australia), J. Callahan, T. Kron, R. Hicks, D. Ball, M. Schneider-Kolsky, M. Mac Manus

42 COMPARISON BETWEEN CT-TARGET VOLUME DELINEATION AND DIFFERENT METHODS OF FDG-PET TARGET VOLUME DELINEATION FOR RADIOTHERAPY PLANNING OF NSCLC
M. Rodari (Italy), P. Navarria, P. Lattuada, M. Scorsetti, A. Chiti

43 DYNAMICS OF HYPOXIA IN HEAD AND NECK CANCER DURING CHEMORADIOTHERAPY EVALUATED WITH [18]F-FLUOROMISONIDAZOLE PET
N. Wiedenmann (Germany), M. Mix, S. Bucher, S. Adebahr, C. Offermann, U. Nestle, W. Weber, A. L. Grosu, M. Hentschel

44 PET ASSESSMENT OF TUMOR PROLIFERATION, METABOLISM AND HYPOXIA BEFORE AND DURING RADIOTHERAPY IN PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC)
B. Dubray (France), P. VERA, A. Edet-Sanson, P. Bohn, A. Salles, S. Hapdey, I. Gardin, J. Menard, L. Thiberville

DOSE PAINTING

INSTRUMENTATION/IMAGE GENERATION/DATA ANALYSIS

NEW RADIOPHARMACEUTICALS

Abstract Nb.

J. Högberg (Sweden), M. Rizell, P. Gjertsson, R. Hultborn, O. Henriksson, J. Himmelman, P. Bernhardt

63 COMPARISON BETWEEN 18F-CHOLINE UPTAKE AND CHOLINE DETECTION IN MR SPECTROSCOPY IN ONE CASE OF BRAIN TUMOUR
R. Sghedoni (Italy), A. Gallina, A. Versari, F. Fioroni, A. Nitrosi, D. Salvo, M. Iori, G. Borasi

PRE-CLINICAL VALIDATION OF TRACERS

Abstract Nb.

64 CT/MR CONTRAST AGENT FOR LONGITUDINAL LOCALIZATION AND DELINEATION OF TARGET STRUCTURES IN IMAGE-GUIDED RADIOTHERAPY
J. Zheng (Canada), C. Allen, D. Jaffray

65 EARLY METABOLOC FLARE FOLLOWING CYTOTOXIC TREATMENT OF SQUAMOUS CELL CARCINOMA IN VITRO
M. Bjurberg (Sweden), P. Abedinpour, E. Kjellen, B. Baldetorp, P. Borgström, J. Wennerberg, E. Brun

66 IMAGING HYPOXIA RESPONSE USING FLUORESCENT AND FLUORINE-18 LABELED SULFONAMIDE INHIBITORS OF CA IX
L. Dubois, N. Lieuwes, J. Secrest, C. Supuran, B. Wouters, H. Kolb, P. Lambin (Netherlands)

RESPONSE EVALUATION/FOLLOW UP

Abstract Nb.

67 18F-FDG PET/CT AS A SELECTION TOOL FOR IMAGE GUIDED RADIOTHERAPY (IGRT) IN PATIENTS WITH RECURRENT OR RESIDUAL OVARIAN CANCER
C. Blumstein (Switzerland), M. Schmuecking, S. Gebhard, S. Perner, C. Kurzeder, S. Reske, D. M. Aebersold, N. Blumstein

68 DIAGNOSTIC PERFORMANCE OF RESPONSE ASSESSMENT FDG-PET/CT IN PATIENTS WITH HEAD & NECK SQUAMOUS CELL CARCINOMA TREATED WITH HIGH-PRECISION DEFINITIVE (CHEMO)RADIATION
T. Gupta (India), S. Jain, J. P. Agarwal, V. Rangarajan, S. Ghosh-Laskar, K. Dinshaw, N. Purandare

Abstract Nb.

69 EARLY PREDICTION OF TREATMENT RESPONSE IN XENOGRAFTS USING QUANTITATIVE DIFFUSION WEIGHTED MRI
T. Seierstad (Norway), K. Røe, S. Folkvord, K. Flatmark, A. Skretting, D. R. Olsen

70 INTRA-TREATMENT FDG POSITRON EMISSION TOMOGRAPHY RESPONSE ASSESSMENT OF ADVANCED HEAD AND NECK CANCER TREATED WITH RADIATION +/- CHEMOTHERAPY
D. Vena (Canada), I. Poon, M. Kusano, B. Smith, S. Campbell, J. Balogh, R. MacKenzie, D. Enepekides, K. Higgins, J. Davidson, S. Singh, C. Caldwell

71 IRON OXIDE PARTICLES COVERED WITH HEXAPEPTIDES TARGETED AT PHOSPHATIDYLSERINE AS MR BIOMARKERS OF TUMOR CELL DEATH
K. Radermacher (Belgium), S. Boutry, S. Laurent, I. Mahieu, L. Vander Elst, C. Bouzin, J. Magat, V. Grégoire, O. Feron, R. Muller, B. Jordan, B. Gallez

72 MOLECULAR IMAGING OF RADIATION RESPONSE IN PRECLINICAL MODELS USING A NOVEL SMALL ANIMAL RADIOTHERAPY SYSTEM
G. Nelson (USA), M. Vilalta, J. Pérez, M. Bazalova, A. J. Giaccia, E. Graves

73 MOLECULAR REMISSION AFTER NEOADJUVANT CHEMORADIATION IN MEDIASTINAL LYMPH NODE METASTASES AS DETECTED BY F-18 FDG PET IN PATIENTS WITH NSCLC
V. Prasad (Germany), M. Schmuecking, R. P. Baum, C. P. Schneider, N. Presselt, J. Leonhardi, K. Hoeffken, K. M. Mueller, T. G. Wendt, R. Bonnet

74 PET SCAN GUIDED INTERSTITIAL BRACHYTHERAPY IN CERVICAL CANCER PATIENTS WITH CLINICALLY SUSPECTED RESIDUAL DISEASE
D. N. Sharma (India), G. K. Rath, S. Kumar, R. Kumar, P. K. Julka, P. Jagadesan, V. Subramani

75 RADIONUCLIDE EVALUATION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
O. Solodyannikova (Ukraine)

76 RESPONSE EVALUATION FOLLOWING CHEMORADIATION WITH NELFINAVIR IN PANCREATIC CARCINOMA – IS FDG-PET CT RELIABLE?
M. Scott-Brown (United Kingdom), A. Cavallaro, T. Brunner

77 STUDY OF THE FOLLOW UP OF SUV AND VOLUME MEASUREMENT OF 18FDG-PET POSITIVE TISSUES DURING RADIOTHERAPY
K. Doyeux, A. Bak, A. Edet-Sanson, B. Dubray, S. Hapdey, D. Gensanne, P. VERA, I. Gardin (France)

Abstract
Nb.

STAGING AND PREDICTION

Abstract
Nb.

78 18F-FDG PET SUVMAX CORRELATES WITH HISTOLOGIC RESPONSE AFTER RADIATION THERAPY FOR CERVICAL CANCER.
J. Leseur (France), A. Devillers, D. Williaume, E. Le Prisé, C. Fougerou, R. De Crevoisier, E. Garin

79 ARE TIMING OF CHEMORADIATION AND EARLY THERAPY RESPONSE AS DETECTED BY F-18 FDG PET PROGNOSTIC FACTORS OF A MULTIMODALITY TREATMENT APPROACH FOR NSCLC STAGE III?
R. P. Baum (Germany), M. Schmuecking, C. P. Schneider, V. Prasad, N. Presselt, J. Leonhardi, K. Hoeffken, K. M. Mueller, T. G. Wendt, R. Bonnet

80 F-18 FLUORODEOXYGLUCOSE UPTAKE IN PRIMARY CERVICAL CANCER AND REGIONAL LYMPH NODES PREDICTS PROGNOSIS AFTER RADIATION THERAPY
W. Sun (USA), S. Bhatia, M. Zimmerman, G. Jacobson

81 MICROVASCULAR LEAKAGE AND CONTRAST ENHANCEMENT ARE PROGNOSTIC FACTORS IN UNFAVORABLE LOW-GRADE GLIOMAS
F. Dhermain (France), D. Ducreux

82 POSITRON EMISSION TOMOGRAPHY (PET) METABOLIC ACTIVITY ASSOCIATED WITH INCREASED RISK OF DEATH IN SUPRAGLOTTIC CARCINOMA PATIENTS TREATED WITH CONCURRENT CHEMORADIATION.
W. Skinner (USA), M. Chamarthy, D. Milstein, M. Haigentz, B. Schiff, R. Smith, S. Kalnicki, M. Garg

83 STAGE IIIB OR IV NSCLC LUNG CANCER ON CT, WHAT IS THE POINT OF F-18 FDG PET/CT?
J. Birchall (United Kingdom), M. Kumar, G. McCulloch

TARGET SELECTION AND DELINEATION

Abstract
Nb.

84 18F-FDG-PET-CT AUTOMATIC TUMOR CONTOURING FOR HEAD AND NECK CANCER RADIOTHERAPY: SIGNAL TO BACKGROUND RATIO METHOD
L. A. Perez Romasanta (Spain), J. Velasco Jiménez, M. Bellón Guardia, E. Lozano Martín, M. Sanz Martín, F. Mendicote León, A. Soriano Castrejón

Abstract Nb.

85 4D PET/CT VALUTATION ON INTEGRATION AND IMPACT IN RADIATION THERAPY PLANNING OF LUNG TUMOR
N. D'Abbiero, M. Paiusco (Italy), A. Versari, F. Fioroni, M. Iori, C. Iotti

86 ADVANTAGES OF FIXED AND ADAPTIVE 18FDG PET/CT BASED BTV DELINEATION IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK : EFFECT ON DOSE ESCALATED IMRT.
M. I. Saunders (United Kingdom), R. Moule, I. Kyani, J. Dickson, C. Lemon, K. Goodchild

87 BIOLOGICAL GROSS TUMOUR VOLUME (GTVB) IN HEAD AND NECK CANCER (HNC): COMPARISON OF AUTOMATED SEGMENTATION TOOLS.
M. Lei (United Kingdom), J. Crawshaw, R. Jena, J. Scuffham, D. Rickard, S. Reise, M. Hatt, J. Hall, J. Sellinger, T. Jordan, S. Whitaker, N. Kirkby, D. Visvikis, A. Nisbet, M. T. Guerrero Urbano

88 CHARACTERIZATION OF A TRIDIMENSIONAL THRESHOLD SEGMENTATION FOR PET TARGET VOLUME DELINEATION
M. Loi (Italy), S. Piras, G. Fara, G. Meleddu, C. Meleddu

89 DISCORDANCE OF TUMOR BOOST VOLUMES DEFINED USING DIFFERENT FUNCTIONAL MRI TECHNIQUES IN THE PROSTATE
S. Riches (United Kingdom), S. Morgan, M. Partridge, G. Payne, D. P. Dearnaley, N. deSouza

90 FOUR-DIMENSIONAL (4D) PET-CT IMAGING IN BASAL LUNG CANCER: DIAGNOSTIC TECHNIQUE OR RADIOTHERAPEUTIC AID?
G. Testanera (Italy), G. Carmela, M. Merra, S. Leonardi, M. Scorsetti, A. Chiti

91 INVESTIGATING THE IMPACT OF THE HIGHLY VARIABLE LYMPHATIC DRAINAGE PATTERN IN PROSTATE CANCER PATIENTS
L. Van den Bergh (Belgium), C. Deroose, S. Joniau, T. Budiharto, F. Mottaghy, E. Lerut, R. Oyen, F. Ameye, K. Bogaerts, H. Van Poppel, K. Haustermans

92 MAGNETIC RESONANCE SPECTROSCOPY OF PROSTATE CANCER FOR RADIOTHERAPY TREATMENT PLANNING
A. Coniglio (Italy), C. Guidi, R. Capparella, A. Santarelli, G. Freixas Vilches, S. La Civita, L. Begnozzi, A. Petrone, G. Mazzarella, L. Marmiroli

93 MET-PET IN THE DELINEATION OF RESIDUAL GLIOBLASTOMA AFTER SURGICAL RESECTION
R. Ciervide (Spain)

Abstract Nb.

Abstract Nb.

S. Kuechler, V. Duncker, F. Momm, E. Schubert, M. Hentschel, N. Hodapp, A. L. Grosu, W. Weber, U. Nestle (Germany), M. Mix

TUMOUR CHARACTERISATION BY MOLECULAR IMAGING

Abstract Nb.

104 A BIOPHYSICAL TRANSPORT MODEL FOR PREDICTING TARGETED MACROMOLECULE TRANSPORT IN SOLID TUMORS
S. Stapleton (Canada), M. Dunne, N. Chaudary, C. Allen, D. Jaffray

105 CAPTOPRIL AND S-NITROSOCAPTOPRIL AS POTENT RADIOSENSITIZERS: COMPARATIVE STUDY AND UNDERLYING MECHANISMS.
B. Jordan (Belgium), J. Peeterbroeck, O. Karroum, C. Diepart, J. Magat, V. Grégoire, B. Gallez

106 CHARACTERIZATION OF FLT-PET RESPONSE TO HIGH- AND LOW-DOSE RADIATION OF A LUNG CANCER XENOGRAFT IN MICE
H. Keller (Canada), D. Vines, M. Lakshman, M. Dunne, P. Lindsay, D. Green, R. Clarkson, R. Bristow

107 DIFFERENT METHODS OF QUANTITATIVE ANALYSIS FOR PATIENT-SPECIFIC DOSIMETRY: PLANAR VERSUS 90Y AND 111IN 3D IMAGING
E. Grassi (Italy), F. Fioroni, A. Versari, D. Salvo, M. Iori

108 EARLY THERAPY CHANGES IN VASCULAR PERMEABILITY PREDICT LONG TERM OUTCOME IN HEAD AND NECK CANCER
D. Brizel (USA), D. Yoo, M. Carroll, J. MacFall, D. Barboriak, G. Broadwater, O. Craciunescu

109 EFFECT OF SHORT AND LONG TERMED HYPOXIA ON THE UPTAKE OF [18F]EF5 AND [18F]FDG
J. Sinkkonen (Finland), A. Silvoniemi, F. Sarita, N. Savisto, O. Solin, R. Grenman, P. Jaakkola, H. Minn, T. Grönroos

110 HYPOXIA PET IMAGING: STATIC VERSUS DYNAMIC SCANS
M. Busk (Denmark), M. R. Horsman, S. Jakobsen, K. V. Hansen, J. Bussink, A. van der Kogel, J. Overgaard

111 MR CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT AFTER ARSENIC TRIOXIDE TREATMENT

Abstract Nb.

C. Diepart (Belgium), O. Karroum, J. Magat, B. Jordan, B. Gallez

112 NON INVASIVE IMAGING OF CETUXIMAB-ZIRCONIUM-89 UPTAKE WITH PET SCANS: A PHASE I TRIAL
J. Van Loon (Netherlands), H. Aerts, D. De Ruysscher, M. Öllers, A. M. Dingemans, M. Hochstenbag, G. Van Dongen, P. Lambin

113 NON INVASIVE MAPPING OF SPONTANEOUS FLUCTUATIONS OF TUMOR OXYGENATION USING 19F-MRI
J. Magat (Belgium), B. Jordan, B. Gallez

114 OPTIMIZED PRODUCTION OF F-LABELED TRACERS ON NEW FULLY AUTOMATED SYNTHESIS PLATFORM
C. Sauvage (Belgium)

115 PROGNOSTIC VALUE OF PRE-RADIOTHERAPY FDG-PET IN ADVANCED HODGKIN' S DISEASE TREATED BY BEACOPP CHEMOTHERAPY REGIMEN
S. Chiesa (Italy), M. C. De Santis, L. Teofili, S. Manfrida, B. Vannata, V. Frascino, A. Fiorentino, L. Calcagni, S. Hohaus, M. Balducci

116 QUANTITATIVE IN VIVO DCE MRI OF PROSTATE CANCER XENOGRAFTS: ASSESSMENT OF ADT AND RT EFFICACY
K. Røe (Norway), T. Seierstad, A. Kristian, G. M. Mælandsmo, A. van der Kogel, A. H. Ree, D. R. Olsen

117 SIMAXSUV, A NEWLY SUGGESTED FDG-PET PARAMETER AS A PROGNOSTIC PREDICTOR IN DIFFUSE LARGE B-CELL LYMPHOMA NEW CASES.
A. Abd El-Ghany (Egypt), W. W. Lee

118 VISUAL AND QUANTITATIVE EVALUATION OF FDG METABOLISM DURING CYTOTOXIC TREATMENT IN TWO PROSPECTIVE CLINICAL TRIALS WITH CORRELATION TO TUMOUR CONTROL
E. Brun (Sweden), M. Bjurberg, E. Kjellen

Author index

Index

AUTHOR INDEX

AUTHOR INDEX